Literature DB >> 1712133

Current status of FK 506 in liver transplantation.

J J Fung1, S Todo, A Tzakis, M Alessiani, K Abu-Elmagd, A Jain, O Bronster, M Martin, R Gordon, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1712133      PMCID： PMC2955871     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  13 in total

1.  Long-term (25-year) survival after renal homotransplantation--the world experience.

Authors:  T E Starzl; G P Schroter; N J Hartmann; N Barfield; P Taylor; T L Mangan
Journal:  Transplant Proc       Date:  1990-10       Impact factor: 1.066

2.  Pathologic observations in human allograft recipients treated with FK 506.

Authors:  A J Demetris; J J Fung; S Todo; B Banner; T Zerbe; G Sysyn; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  FK 506 as a growth control factor.

Authors:  A Francavilla; M Barone; T E Starzl; A Zeevi; C Scotti; G Carrieri; V Mazzaferro; J Prelich; S Todo; G Eiras
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

4.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

5.  Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

Authors:  T Ochiai; K Nakajima; M Nagata; T Suzuki; T Asano; T Uematsu; T Goto; S Hori; T Kenmochi; T Nakagoori
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

6.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase.

Authors:  M W Harding; A Galat; D E Uehling; S L Schreiber
Journal:  Nature       Date:  1989-10-26       Impact factor: 49.962

8.  Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy.

Authors:  N Murase; D G Kim; S Todo; D V Cramer; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1990-08       Impact factor: 4.939

9.  Liver, kidney, and thoracic organ transplantation under FK 506.

Authors:  S Todo; J J Fung; T E Starzl; A Tzakis; A J Demetris; R Kormos; A Jain; M Alessiani; S Takaya; R Shapiro
Journal:  Ann Surg       Date:  1990-09       Impact factor: 12.969

10.  Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

Authors:  S Todo; Y Ueda; J A Demetris; O Imventarza; M Nalesnik; R Venkataramanan; L Makowka; T E Starzl
Journal:  Surgery       Date:  1988-08       Impact factor: 3.982
View more
  7 in total

1.  Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Long-term insulin requirement after liver transplantation with FK 506 in American veterans.

Authors:  J Tabasco-Minguillan; L Mieles; P Carroll; J Gavaler; D H Van Thiel; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

Review 3.  Immunosuppressive drugs in paediatric liver transplantation.

Authors:  I D van Mourik; D A Kelly
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506.

Authors:  P M Markus; X Cai; W Ming; A J Demetris; J J Fung; T E Starzl
Journal:  Transplantation       Date:  1991-10       Impact factor: 4.939

5.  Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation.

Authors:  Walter S Bartynski; Zella R Zeigler; Richard K Shadduck; John Lister
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

6.  A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.

Authors:  M Martin; R Mañez; P Linden; D Estores; J Torre-Cisneros; S Kusne; L Ondick; R Ptachcinski; W Irish; D Kisor
Journal:  Transplantation       Date:  1994-10-15       Impact factor: 4.939

Review 7.  Liver transplantation: history, outcomes and perspectives.

Authors:  Roberto Ferreira Meirelles Júnior; Paolo Salvalaggio; Marcelo Bruno de Rezende; Andréia Silva Evangelista; Bianca Della Guardia; Celso Eduardo Lourenço Matielo; Douglas Bastos Neves; Fernando Luis Pandullo; Guilherme Eduardo Gonçalves Felga; Jefferson André da Silva Alves; Lilian Amorim Curvelo; Luiz Gustavo Guedes Diaz; Marcela Balbo Rusi; Marcelo de Melo Viveiros; Marcio Dias de Almeida; Pamella Tung Pedroso; Rodrigo Andrey Rocco; Sérgio Paiva Meira Filho
Journal:  Einstein (Sao Paulo)       Date:  2015 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.